Early intervention of chronic kidney diseases (CKD) could save $ 1 billion in Australia a year in Australia[1]

Sydney,, June 7, 2025 / Prnewswire / – A new modeling highlights the potential advantages of the company, economic and environmental of the early intervention of chronic kidney disease (CKD) which could change their lives for thousands of Australians.

Australia could save 25.2 billion dollars In CKD -related costs and more than the demand for dialysis in two over 25 years with early action.¹ The model projects additional gains for the Australian economy and the company with projections showing that an increase of $ 1.6 billion in net tax revenues could be carried out over the same period and 200,000 additional people on the labor market.¹

It is estimated that 2.7 million people in Australia are currently living with signs of CKD.² The disease costs at least the Australian economy at least $ 9.9 billion One year.³

The recently published results of the Impact CKD modeling analysis by Astrazeneca suggest that political measures targeting CKD could unlock large -scale societal advantages across Australia. Early action pressure can be reduced on the health system, which stimulates economic productivity while improving the lives of people living with CKD.

The impact of the CKD simulation modeled the results for the Australian population over a period of 25 years, from 2022 to 2047, in order to explore the potential impact of early intervention.¹ It assessed the combined effect of detection, previous diagnosis and better access to processing, including annual targeted tests for high -risk individuals and improving the use of medical lines led by guidelines (GDMT).

Modeling has projected significant improvements in health results in Australia Including a reduction of 48.1% of cardiovascular events (CV) and a decrease of 7.3% of mortality all causes over 25 years.¹ These results were accompanied by a 55%planned dialysis reduction, one of the most high -intensity of resources in CKD care.¹ Consequently, health costs related to ACK in Australia should decrease by 10.9%, which led to an estimate

$ 25.2 billion savings over the same period.¹

Beyond clinical and economic implications, modeling also indicated that the reduction in dependence on dialysis could reduce the consumption of fresh water replacement (KRT) by 51.0%, the use of fossil fuels of 48.2% and carbon emissions of 48.1%¹ – Offer significant environmental advantages that correspond to the national health and climate strategy of the Australian government.

Ben McDonaldPresident of Pays d’Astrazeneca Australia and New Zealandsaid the results demonstrate the opportunity we have in Australia to reduce the health and economic burden of the IRC.

“Anterior access to diagnosis and treatment improves results for patients, can slow renal progression and help avoid dialysis costs. With the right concentration and investment, we can create system -scale advantages for people, society and the planet, said McDonald.

“IncreaseSing the early detection and treatment of IRC in Australia should be a public health priority. The Australian health system can do more to work with people who run at high risk of having MCDs but who may not know. “”

Chris Forbes, CEO of Kidney Health Australia (Kha), praised the results.

“Early diagnosis can make a difference that changes their life for Australians living with CKDs. It is time to deactivate the tap. Early detection offers patients the best opportunity to treat the disease – slow down or even stop progression to kidney failure and avoid the significant assessment of dialysis, said Forbes.

“Too many people slide through the meshes of the net until it is too late. Our ambition is a future where each Australian has the ability to take advantage of excellent kidney health. We need urgent political action to support previous detection and timely access to treatment.”

NOTEs to publishers

Impact CKD is the first study to examine and predict the vast impact of the CKD on a 25 -year horizon.¹ It is based on a framework of conceptual diseases developed by researchers London Economy School In consultation with more than 60 international and Australian experts. Impact CKD is part of Astrazeneca’s goal to improve CKD understanding and results worldwide. Astrazeneca and the Global Patient Alliance for Kidney Health (Glopakh) were launched ‘Change for kidney health’ Campaign to educate political decision -makers and leaders of the health system. This initiative aims to raise the IRC in the World Policy Program, arguing for complete and effective disease management strategies to combat this growing health challenge.

The new impact BMI results occur only a few days after the World Health Assembly has adopted a new resolution recognizing CKD as a global public health priority which is an essential step that increases ACD in other major non -transmitted diseases such as cancer, cardiovascular disease and diabetes.⁴

About CKD

IRC is a silent disease to a late stage.⁵ Nearly 850 million people worldwide⁶and around 2.7 million people Australia have CKD biomarkers, with 2.5 million

Unheeded and ignored Australians have signs of the disease.² The most common causes of CKD include diabetes and hypertension. The IRC is associated with a significant morbidity of patients and an increased risk of cardiovascular events, such as myocardial infarction and heart failure (HF), which leads to premature death.⁷ In its most severe form, known as renal insufficiency, renal lesions and the deterioration of kidney function have progressed to the point where dialysis or renal transplantation are necessary. CKD patients are more likely to die from CV disease than to progress for a renal stadium disease.⁸

Show the original content:https://www.prnewswire.com/apac/News-releases/early-chronic-kidney-distease-ckd-ckd- intervention-could-save-australia-1-billion-a-30247523.html

Source Astrazeneca

Source: PR Newswire